Immunology Topic Homepage

Learning Zones

,Lernbereich symptomatisches Asthma

Dieses Fortbildungsmaterial wurde für Gesundheitsexperten in Europa, die mit der Versorgung von Asthma-Patienten betraut sind, entwickelt.

Mehr Bewusstsein für die Krankheit - Dieser Bereich liefert Hintergrundinformationen zu den Auswirkungen des symptomatischen Asthmas und klärt über potenzielle Behandlungsstrategien auf.

RCGP-akkredierte CME - Im Rahmen der Maßnahmen zur kontinuierlichen berufsbegleitenden Fortbildung für Ärzte (CME) können Sie mehr über die Behandlung des symptomatischen Asthmas in der Praxis aus der Perspektive der Ärzte erfahren. In vier Runden erörtern Richard Russell und Thys van der Molen folgende Themen:

  1. Was ist Asthmakontrolle: Wer, warum und wie viele?
  2. Verbesserung der Asthmakontrolle in der Gemeindeversorgung
  3. Derzeitige Standardbehandlung bei Asthma
  4. Pro und Contra zusätzlicher Add-on-Therapien

Wenn Sie den Evaluierungsfragebogen vollständig ausfüllen, wird Ihnen eine Stunde für Ihr CPD-Zertifikat angerechnet.

SPIRIVA® Respimat® ist in der Europäischen Union, Japan, USA und vielen anderen Ländern für die Anwendung bei Asthma zugelassen. Die Indikation ist von Land zu Land verschieden. Dieses Fortbildungsmaterial kann daher Informationen über Medikationen enthalten, für die in Ihrem Land möglicherweise keine Indikationen zugelassen sind.

,Zone d’apprentissage de l’asthme symptomatique

Ces ressources pédagogiques ont été développées pour les professionnels de la santé en Europe, impliqués dans la prise en charge de patients asthmatiques.

Sensibilisation à la maladie – Cette section fournit des informations générales à propos de l’impact de l’asthme symptomatique et de stratégies de prise en charge potentielles.

FMC accréditée par le RCGP – Au sein des activités de Formation Médicale Continue (FMC), vous aurez accès aux perspectives de médecins sur la prise en charge pratique de l’asthme symptomatique. Richard Russell et Thys van der Molen abordent ce sujet au cours de quatre sessions :

  1. Qu’est-ce que le contrôle de l’asthme: qui, pourquoi et combien ?
  2. Améliorer le contrôle de l’asthme dans la communauté
  3. Traitement actuel standard de l’asthme
  4. Avantages et inconvénients de traitements d’appoint supplémentaires

Répondez au questionnaire d’évaluation et une heure sera ajoutée à votre DPC.

SPIRIVA® Respimat® est approuvée contre l’asthme dans l’Union Européenne, le Japon, les Etats-Unis et de nombreux autres pays. Les indications varient d’un pays à l’autre et les ressources pédagogiques peuvent contenir des informations sur des médicaments dont les indications ne sont pas approuvées dans votre pays.

,Área de aprendizagem sobre a asma sintomática

Este recurso educativo foi desenvolvido para profissionais de saúde na Europa envolvidos na prestação de cuidados a doentes asmáticos.

Sensibilização para a doença – Esta secção apresenta informações de referência relativas ao impacto da asma sintomática e a potenciais estratégias de gestão.

FMC acreditada pelo RCGP – No âmbito da atividade de formação médica contínua (FMC), pode tomar conhecimento das perspetivas dos médicos a respeito da gestão da asma sintomática na prática. Richard Russell e Thys van der Molen discutem em quatro sessões:

  1. Em que consiste o controlo da asma: quem, porquê e quantos?
  2. Melhorar o controlo da asma na comunidade
  3. Tratamento atual de referência para a asma
  4. Vantagens e desvantagens do tratamento complementar adicional

Ser-lhe-á creditada uma hora de DPC se responder com sucesso ao questionário de avaliação

O SPIRIVA® Respimat® está aprovado para utilização na asma na União Europeia, no Japão, nos EUA e em muitos outros países. A indicação varia em função do país e o recurso educativo poderá conter informação sobre medicamentos cujas indicações poderão não estar aprovadas no seu país.

,Zona de aprendizaje sobre el asma sintomática

Este recurso educativo ha sido elaborado por profesionales sanitarios de Europa que intervienen en la atención de pacientes con asma.

Concienciación sobre la enfermedad: Esta sección proporciona información general relativa al impacto del asma sintomática y a las posibles estrategias de tratamiento.

EMC homologada por el RCGP: Como parte de la actividad de educación médica continuada (EMC), puede aprender sobre las perspectivas de los médicos sobre el tratamiento del asma sintomática en la práctica clínica. Richard Russell y Thys van der Molen comentan en cuatro sesiones:

  1. Qué es el control del asma: ¿quién, por qué y cuántos?
  2. Mejorar el control del asma en el ámbito extrahospitalario
  3. Tratamiento de referencia actual para el asma
  4. Ventajas e inconvenientes del tratamiento complementario adicional

Se concederá una hora para la consecución de su crédito de DPP tras haber superado con éxito el cuestionario de evaluación.

SPIRIVA® Respimat® está autorizado para su uso en el asma en la Unión Europea, Japón, EE. UU. y muchos otros países. La indicación varía según el país y este recurso educativo puede contener información sobre medicamentos que no estén aprobados en su país para las indicaciones mencionadas.

,Spazio di apprendimento sull’asma sintomatico

Queste risorse didattiche sono state sviluppate per i professionisti del settore sanitario europei che operano nel campo dell’assistenza ai pazienti affetti da asma.

Sensibilizzazione – Questa sezione fornisce informazioni generali sugli effetti dell’asma sintomatica e sulle potenziali strategie di gestione.

CME accreditata dall'RCGP – All’interno delle attività di educazione medica continua (CME), puoi scoprire le prospettive mediche per la gestione pratica dell’asma sintomatica. Richard Russell e Thys van der Molen discutono in quattro sessioni di:

  1. Cos’è il controllo dell’asma: chi, perché e quanti?
  2. Migliorare il controllo dell’asma nella comunità
  3. L’attuale trattamento standard dell’asma
  4. Pro e contro dellla terapia aggiuntiva.

Il CPD (Sviluppo Professionale Continuo) ti sarà riconosciuto un’ora dopo, dietro superamento del questionario valutativo.

SPIRIVA® Respimat® è autorizzato per la cura dell’asma nell’Unione Europea, in Giappone, negli Stati Uniti e in molti altri Paesi. Le indicazioni variano da Paese a Paese e le risorse didattiche possono contenere informazioni su farmaci le cui indicazioni potrebbero non essere approvate nel tuo Paese.

,CSU Knowledge Centre and CME

The Chronic Spontaneous Urticaria (CSU) Knowledge Centre and CME has been developed to address the current lack of early diagnosis of this condition.

Allergists, immunologists, dermatologists and other healthcare professionals will find a range of content to support the effective diagnosis and treatment of this condition.

Sections are regularly updated and include a disease overview, congress and symposium highlights, case studies, a video channel, FAQs answered by CSU experts, accredited CME and additional resources (including an events calendar, infographics, information on the TARGET My Hives app and useful external links).

,Symptomatic Asthma Learning Zone

This educational resource has been developed for healthcare professionals in Europe who are involved in the care of patients with asthma.

Disease Awareness - This section provides background information regarding the impact of symptomatic asthma and potential management strategies.

RCGP-accredited CME - Within the continuing medical education (CME) activity, you can learn about physician perspectives on managing symptomatic asthma in practice. Richard Russell and Thys van der Molen discuss in four sessions:

  1. What is asthma control: Who, why and how many?
  2. Improving asthma control in the community
  3. Current standard asthma treatment
  4. Pros and cons of additional add-on treatment.

One hour towards your CPD will be rewarded upon successful completion of the evaluation questionnaire

SPIRIVA® Respimat® is approved for use in asthma in the European Union, Japan, USA and many other countries. The indication varies by country and the educational resource may contain information about medications for which indications may not be approved in your country.

,

Psoriasis is a chronic inflammatory disease affecting approximately 2% of the world’s population. The Psoriasis Knowledge Centre provides dermatologists, family medicine doctors and other healthcare professionals with relevant information including epidemiology, pathophysiology, diagnosis and more.

A treatment section reviews the established treatments available for psoriasis and considers their modes of action, available clinical data and place in the therapeutic pathway.

Also located within the Psoriasis Knowledge Centre is a dedicated educational section focusing on IL-17A in Psoriasis. This free resource is intended to provide healthcare professionals with information on the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A.

,IL-17A Header

Located within the Psoriasis Knowledge Centre, IL-17A in Psoriasis has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A.

Content is arranged within multiple sections that are easy to navigate. Users can find expert videos, clinical slide decks on topics such as disease pathophysiology and emerging therapies, congress highlights, key publications and links to useful resources.

This free resource is intended for healthcare professionals involved in the treatment and management of patients with psoriasis.

This resource has been developed in collaboration with Novartis Pharma AG.

Clinical Case Studies

Management of Acute Uncomplicated Pyelonephritis

Infection: Genitourinary Infection

Beryl Oppenheim, Consultant Microbiologist, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK

Case History
A 37-year-old woman presented to an accident and emergency department. She complained to the assessing doctor that she had had severe right loin pain and had been experiencing fevers and shivering for the past 24 hours.

Guillain-Barré Syndrome

Respiratory Medicine & Allergy: Sleep apnoea/hypopnoea & respiratory failure

Nicholas Hopkinson, Consultant Respiratory Physician, Royal Brompton and Harefield NHS Foundation Trust, London, UK
Christopher Kosky, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK

Case History
A 34-year-old male civil servant presented to the emergency department with a three-day history of malaise and tingling in his hands and feet. He described weakness such that he was unable to get out of the bath unaided.

Latest News

Blog

The 2003 British Thoracic Society and Scottish Intercollegiate Guidelines Network asthma management guidelines use the international consensus definition to describe asthma as:
“a chronic inflammatory disorder of the airways. In susceptible individuals inflammatory symptoms are usually associated with widespread but variable airflow obstruction and an increase in airway response to a variety of stimuli. Obstruction is often reversible either spontaneously or with treatment”.

During an asthma attack, also called an asthma exacerbation, airways become swollen and inflamed. The muscles around the airways contract narrowing the bronchial tubes.
Asthma attacks can be minor which improve with home treatment, or severe which can become a life threatening emergency.

This post discusses clinical assessment and treatment of patients with acute asthma exacerbations.

Medical Videos

An Animation Demonstrating the Role of Natural Killer Cells
An Animation Demonstrating the Role of Natural Killer Cells
An Animation of The Main Roles of the Immune System
An Animation of The Main Roles of the Immune System

Recent Drug Updates

Medical Journal Abstracts on Immunology

Imatinib: a breakthrough of targeted therapy in cancer.

Thu 19 May 2016 -  Imatinib: a breakthrough of targeted therapy in cancer.

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach ...

The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis.

Sun 01 May 2016 -  The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis.

Vedolizumab, an α4β7-integrin antagonist, is the first gut-selective monoclonal antibody that has been approved for the treatment of moderate-to-severe ulcerative colitis and Crohn's ...

Medical Images

Hypersensitivity Pneumonitis
Hypersensitivity Pneumonitis
gp120 and the CCR5 co-receptor
 gp120 and the CCR5 co-receptor
Key events leading up to the era of HAART
Key events leading up to the era of HAART
Large cerebral tuberculoma on MRI
Large cerebral tuberculoma on MRI
Grocott stain
Grocott stain
Sickle cell lung disease
Sickle cell lung disease
Metavir stage 4 (F4)
Metavir stage 4 (F4)
Allergic Bronchopulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis
Febrile respiratory illness - chest X-ray
Febrile respiratory illness - chest X-ray
HIV infected adults (15 years and above) who are female in %
HIV infected adults (15 years and above) who are female in %

Clinical Guidelines

Myeloma: diagnosis and management

Feb 2016

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and..

... primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

This guideline includes recommendations on:
   - communication and support
   - laboratory investigations
   - imaging investigations
   - managing newly-diagnosed and relapsed myeloma
   - preventing and managing bone disease and other complications
   - monitoring

Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma

Nov 2015

The objective of this guideline is to provide healthcare professionals with guidance on the..

... investigation and management of patients with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). Individual patient circumstances may dictate an alternative approach. This is the first BCSH guideline on this topic and is in date at time of publication.

Clinical Trials

A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age

Sun 01 May 2016

The purpose of this study is to assess the safety and immunogenicity of different formulations of GSK Biologicals' influenza candidate vaccine GSK1557484A, in children 6-35 months of ...

Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial (Hypogamma Int1)

Sun 01 May 2016

The study will investigate the efficacy and safety of subcutaneous interferon alpha -2a to eradicate rhinovirus in patients with primary hypogammaglobulinemia. Patients with hypogammaglobulinemia ...

Back to top